Advertisement
Articles
Advertisement

Focus on Funding 5/12/06

Fri, 05/12/2006 - 9:10am


GOVERNMENT FUNDING

NIAID Awards $3.4M for HIV Liver Damage Study
Researchers at the University of Cincinnati, Ohio, Academic Health Center received a $3.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate liver injury after use of antiretroviral drugs in HIV-infected patients with hepatitis C.
Full Article

INDIVIDUAL GIFTS

University of Chicago Receives $25M Gift
Melvin and Ellen Gordon donated $25 million toward the University of Chicago’s largest science building, which will allow scientists could pursue innovative integrative science that crosses traditional boundaries between physics, chemistry, and biology.
Full Article

UCSF Institute for Regeneration Medicine Receives $16M Gift
Ray and Dagmar Dolby donated $16 million to the University of California, San Francisco (UCSF), to construct the UCSF Institute for Regeneration Medicine that will allow scientists to develop cell-based therapies for diseases.
Full Article

$100M Gift for Cancer Research Facility
Memorial Sloan-Kettering Cancer Center, New York, received a commitment from publisher, real estate developer, and hospital board member Mortimer Zuckerman of $100 million toward its new cancer research facility, the largest single commitment by an individual in its history.
Full Article

PRIVATE FUNDING

Gilead Invests $25M in Corus
Gilead Sciences Inc., Foster City, Calif., invested $25 million in Corus Pharma Inc., Seattle, Wash., which develops novel drugs for respiratory diseases. Gilead also has an exclusive option to purchase the remainder of Corus Pharma.
Full Article

Sirtris Secures $37M in New Financing
Sirtris Pharmaceuticals, Cambridge, Mass., secured $37 million in new financing between Series C equity placement and venture debt, which will allow it to accelerate its therapeutic programs focused on metabolic and neurological diseases.
Full Article

Dynavax Receives $50M Funding
Dynavax Technologies Corp., Berkeley, Calif., received an investment of $50 million to advance its cancer, hepatitis B, and hepatitis C therapeutic programs through clinical development.
Full Article

Cardiokine Closes on $50M in Series B Funds
Cardiokine Inc., Philadelphia, which develops drugs to treat and prevent heart failure and related cardiovascular and metabolic indications, closed on a $50 million Series B preferred share equity offering, to initiate phase III trials for its lead product candidate Lixivaptan.
Full Article

KAI Secures $35M in Series B Financing
KAI Pharmaceuticals Inc., South San Francisco, completed $35 million Series B private equity financing, which will be used to fund KAI's research and development pipeline of protein kinase C therapeutics aimed at various diseases and pain conditions.
Full Article

Aerovance Receives $60M in Series C Funding
Aerovance Inc., Berkeley, Calif., secured $60 million in Series C financing, which will be used to advance the development of its portfolio of clinical-stage drugs targeting severe respiratory and inflammatory diseases.
Full Article

GRANTS AVAILABLE

Memory T Lymphocytes in Cancer Immunology
Agency: National Cancer Institute
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This announcement solicits applications from organizations to conduct basic research studies that are relevant to anti-tumor immunity and focused on memory T lymphocytes and/or the cells and molecules that interact with them.
Full Article

Nuclear Structure-Function Defects in the Pathogenesis of Muscular Dystrophy
Agency: National Institutes of Health
Estimated Funding: $2,000,000
Due Date for Applications: September 21, 2006
Description: This announcement invites applications to determine the mechanisms of a subset of muscular dystrophies, particularly Emery-Dreifuss, facioscapulohumeral, limb girdle muscular dystrophy 1B, and oculopharyngeal muscular dystrophies.
Full Article

Biomarker Development for Diabetic Complications
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: December 13, 2006
Description: This announcement seeks grant applications for exploratory and developmental research on biomarkers for the microvascular and macrovascular complications of diabetes. Eight to twelve awards of varying sizes are anticipated.
Full Article

Pilot and Feasibility Clinical Research Grants in Kidney or Urologic Diseases
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This announcement solicits applications for pilot clinical and translational research studies, related to kidney or urologic disease research that could lead to full-scale clinical studies to diagnose, prevent, pre-empt, or treat kidney or urologic disease.
Full Article

In Vivo Cancer Imaging Exploratory/Developmental Grants
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This announcement invites exploratory/developmental applications articulating high risk and/or high impact research focused on the entire spectrum of in vivo cancer imaging for detection, diagnosis, and monitoring of response to therapy.
Full Article

Innovative Technologies for Molecular Analysis of Cancer
Agency: National Cancer Institute
Estimated Funding: $200,000
Due Date for Applications: September 22, 2006
Description: The National Cancer Institute seeks exploratory grant applications for research projects to develop highly innovative cancer-relevant molecular biology technologies, including, but not limited to, instrumentation, techniques, and devices.
Full Article

Application of Emerging Technologies for Cancer Research
Agency: National Cancer Institute
Estimated Funding: $275,000 for up to two years
Due Date for Applications: September 22, 2006
Description: This announcement solicits grant applications for research projects to develop highly innovative cancer-relevant molecular biology technologies as part of a broader Institute-sponsored Innovative Molecular Analysis Technologies Program.
Full Article

Innovations in Cancer Sample Preparation
Agency: National Institutes of Health
Estimated Funding: $500,000
Due Date for Applications: September 22, 2006
Description: This announcement seeks applications for research projects to develop and enhance sample preparation methodologies and technologies, and develop assays to assess sample quality, in order to optimize the usefulness of samples.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading